Patent intelligence · US
US 11813278
Highly active compounds against COVID-19
Highly active compounds against COVID-19
Patent details — US 11813278
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 14, 2023
- Expiration
- Nov 9, 2043
- Applicant
- Atea Pharmaceuticals, Inc.
- Claims
- 37
- CPC classes
- A61K, A61K31/706, A61K31/7064, A61K31/7076
Quick answer
US 11813278 (Highly active compounds against COVID-19) is held by Atea Pharmaceuticals, Inc.. Status: granted. Granted Nov 14, 2023. Expires Nov 9, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Atea Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 37
- CPC classes
- A61K, A61K31/706, A61K31/7064, A61K31/7076, A61K9/0019, A61K9/0053
More from Atea Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12226429
Highly active compounds against COVID-19
granted -
US 12084473
β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
granted -
US 12006340
Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
granted -
US 12005139
Ophthalmic formulations and related methods
granted -
US 11975016
2′-substituted-N6-substituted purine nucleotides for RNA virus treatment
granted -
US 11964047
Ophthalmic formulations and related methods
granted -
US 11833160
Ursodeoxycholic acid derivatives as HDAC inhibitors for the treatment of polycystic diseases
granted
Frequently asked questions
What is US patent 11813278?
US 11813278 (Highly active compounds against COVID-19) is held by Atea Pharmaceuticals, Inc.. Status: granted. Granted Nov 14, 2023. Expires Nov 9, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11813278?
Atea Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 35 pharmaceutical patents for this assignee.
When does US 11813278 expire?
Our index shows an expiration date of Nov 9, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.